Conference item icon

Conference item : Abstract

P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)

Abstract:

Background: In GEMINI 1, UC response to vedolizumab (VDZ) was 47% at Week 6 and 42% by Week 52. Our aim was to assess real-life outcomes for VDZ in UC. Methods: Data collected at 12 Australian (Aus), 1 UK and 2 Hong Kong (HK) centres, assessed response to VDZ at 3, 6, and 12 months using the Mayo Clinic Score (MCS, Aus/HK) or SCCAI and UCEIS (UK). Results: Two hundred and ninety-three patients (53% male, median age 38 years, 196 Aus, 93 UK, 4 HK) were assessed with similar age, disease locati...

Expand abstract
Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Files:
Publisher copy:
10.1093/ecco-jcc/jjx180.698

Authors


Expand authors...
Publisher:
Oxford University Press Publisher's website
Journal:
Journal of Crohns and Colitis Journal website
Volume:
12
Issue:
S1
Pages:
S395-S396
Host title:
Journal of Crohns and Colitis; 13th Congress of ECCO – European Crohn’s and Colitis Organisation
Publication date:
2018-01-16
Acceptance date:
2018-01-15
DOI:
EISSN:
1876-4479
ISSN:
1873-9946
Source identifiers:
844107

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP